Rimonabant effective in Type 2 Diabetes « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Rimonabant effective in Type 2 Diabetes

Posted on June 11, 2008 by crimsoncanary

Clinical data presented at ADA show Sanofi-aventis’ CB1 antagonist rimonabant significantly improved glucose levels (as measured by HbA1c) compared to controls in patients with type 2 diabetes

Filed under: gpcr | Tagged: antagonist, Sanofi-Aventis, Cannabinoid, Rimonabant, Acomplia, Slimona, SR-141716, SR-141716A, Zimulti, SR141716, SR141716A, CB1

« Targacept and AstraZeneca Initiate Phase II Trial of Neuronal Nicotinic agonist AZD3480 Researchers from the Italy publish series of Pyrrolidinylfuran Muscarinic M2 agonists »

Leave a Reply